RLYB · Insider Trading
Rallybio Corporation Common Stock
Every open-market purchase and sale reported by RLYB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-20 | Helen M Boudreau | Director | M | +2,062 | +$31.51K |
| 2026-10-20 | Paula Soteropoulos | Director | M | +3,562 | +$8.48K |
| 2026-10-14 | Robert Lorne Hopfner | Director | M | +14,820 | +$109.87K |
| 2026-10-13 | Jonathan I Lieber | Chief Financial Officer | M | +3,910 | +$23.77K |
| 2026-10-08 | Stephen Uden | Chief Executive Officer | M | +22,456 | +$136.53K |
| 2026-10-01 | Jonathan I Lieber | Chief Financial Officer | M | +5,000 | +$30.40K |
| 2026-09-28 | Hui Liu | Director | M | +12,044 | +$72.94K |
| 2026-09-18 | Wendy Chung | Director | M | +3,562 | +$8.48K |
| 2026-07-10 | Helen M Boudreau | Director | M | +3,562 | +$8.48K |
| 2026-05-20 | Daniel Schneeberger | 10%+ Owner | Buy | +32,418 | +$453.13K |
| 2026-05-15 | ADAR1 Capital Management, LLC | 10%+ Owner | Buy | +159,118 | +$2.23M |
| 2026-05-13 | Daniel Schneeberger | 10%+ Owner | Buy | +101,600 | +$1.42M |
| 2026-05-06 | ADAR1 Capital Management, LLC | 10%+ Owner | Buy | +311,810 | +$4.36M |
| 2026-02-23 | Jonathan I Lieber | Chief Financial Officer | MIXED | +1,711 | −$3.99K |
| 2026-02-20 | Martin Mackay | Director | A | +18,055 deriv. | — |
| 2026-02-20 | Ronald Hunt | Director | A | +14,305 deriv. | — |
| 2025-05-15 | Helen M Boudreau | Director | A | +28,500 deriv. | — |
| 2025-05-15 | Wendy Chung | Director | A | +28,500 deriv. | — |
| 2025-05-15 | Ronald Hunt | Director | A | +28,500 deriv. | — |
| 2025-05-15 | Robert Lorne Hopfner | Director | A | +28,500 deriv. | — |
| 2025-05-15 | Hui Liu | Director | A | +28,500 deriv. | — |
| 2025-05-15 | Paula Soteropoulos | Director | A | +28,500 deriv. | — |
| 2025-05-15 | Martin Mackay | Director | A | +28,500 deriv. | — |
| 2025-05-15 | Christine A Nash | Director | A | +28,500 deriv. | — |
| 2025-02-19 | Jonathan I Lieber | Chief Financial Officer | A | +180,000 deriv. | — |
| 2025-02-19 | Stephen Uden | Chief Executive Officer | A | +453,700 deriv. | — |
| 2025-02-19 | Steven Ryder | Chief Medical Officer | A | +180,000 deriv. | — |
| 2025-01-06 | Martin Mackay | Director | A | +92,857 deriv. | — |
| 2025-01-06 | Robert Lorne Hopfner | Director | A | +73,571 deriv. | — |
| 2025-01-06 | Hui Liu | Director | A | +67,857 deriv. | — |
| 2025-01-06 | Ronald Hunt | Director | A | +73,571 deriv. | — |
| 2024-05-17 | Wendy Chung | Director | A | +16,500 deriv. | — |
| 2024-05-17 | Christine A Nash | Director | A | +16,500 deriv. | — |
| 2024-05-17 | Robert Lorne Hopfner | Director | A | +16,500 deriv. | — |
| 2024-05-17 | Ronald Hunt | Director | A | +16,500 deriv. | — |
| 2024-05-17 | Helen M Boudreau | Director | A | +16,500 deriv. | — |
| 2024-05-17 | Hui Liu | Director | A | +16,500 deriv. | — |
| 2024-05-17 | Kush Parmar | Director | A | +16,500 deriv. | — |
| 2024-05-17 | Paula Soteropoulos | Director | A | +16,500 deriv. | — |
| 2024-02-16 | Martin Mackay | Executive Chairman | A | +216,000 deriv. | — |
| 2024-02-16 | Steven Ryder | Chief Medical Officer | A | +120,000 deriv. | — |
| 2024-02-16 | Jonathan I Lieber | Chief Financial Officer | A | +120,000 deriv. | — |
| 2024-02-16 | Stephen Uden | Chief Executive Officer | A | +216,000 deriv. | — |
| 2024-01-04 | Ronald Hunt | Director | A | +29,096 deriv. | — |
| 2024-01-04 | Kush Parmar | Director | A | +27,118 deriv. | — |
| 2023-05-19 | Robert Lorne Hopfner | Director | A | +15,490 deriv. | — |
| 2023-05-19 | Helen M Boudreau | Director | A | +15,490 deriv. | — |
| 2023-05-19 | Kush Parmar | Director | A | +15,490 deriv. | — |
| 2023-05-19 | Christine A Nash | Director | A | +15,490 deriv. | — |
| 2023-05-19 | Hui Liu | Director | A | +15,490 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Daniel Schneeberger | 10%+ Owner | 926,152 | $15.42M |
| ADAR1 Capital Management, LLC | 10%+ Owner | 909,843 | $15.15M |
| Ronald Hunt | Director | 249,239 | $4.15M |
| Robert Lorne Hopfner | Director | 220,994 | $3.68M |
| Stephen Uden | Chief Executive Officer | 115,620 | $1.93M |
| Martin Mackay | Executive Chairman | 89,329 | $1.49M |
| Jonathan I Lieber | Chief Financial Officer | 13,650 | $227.27K |
| Hui Liu | Director | 12,044 | $200.53K |
| Helen M Boudreau | Director | 8,604 | $143.26K |
| Paula Soteropoulos | Director | 6,544 | $108.96K |
| Wendy Chung | Director | 3,562 | $59.31K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RLYB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.